Please login to the form below

Not currently logged in
Email:
Password:

Rexulti

This page shows the latest Rexulti news and features for those working in and with pharma, biotech and healthcare.

Lundbeck and Otsuka start phase III for Rexulti in bipolar

Lundbeck and Otsuka start phase III for Rexulti in bipolar

Otsuka and co-development partner Lundbeck have started two phase III trials of their atypical antipsychotic Rexulti in bipolar disorder, potentially adding a third indication for the drug. ... To date Rexulti has only been launched in the US, Canada and

Latest news

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics